Top pharmaceutical companies

UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a

AstraZeneca, Honeywell partner to address climate change with new inhaler tech

https://pharmaphorum.com/news/astrazeneca-honeywell-partner-to-address-climate-change-with-new-inhaler-tech/

Merck Inc/ News

27 drugmakers to provide generic COVID drug to low-income countries

Jonah Comstock 0 Comment

Twenty-seven drug makers have signed onto a deal to manufacture a generic version of molnupiravir, Merck’s oral antiviral

27 drugmakers to provide generic COVID drug to low-income countries

https://pharmaphorum.com/news/27-drugmakers-to-provide-generic-covid-drug-to-low-income-countries/

AstraZeneca/ News/ News/ R&D

Breakthrough designation AstraZeneca’s severe asthma drug

Piotr Wnuk Amgen, AstraZeneca, severe asthma, tezepelumab 0 Comment

The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after

Breakthrough designation AstraZeneca’s severe asthma drug

https://pharmaphorum.com/news/astrazeneca-asthma-breakthrough/

GlaxoSmithKline/ News/ Top stories/ US

GSK cuts 650 jobs in the US

Piotr Wnuk GlaxoSmithKline 0 Comment

GlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to

GSK cuts 650 jobs in the US

https://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/

News/ Novartis/ Top stories/ US

Novartis sells parts of Sandoz for $1bn

Piotr Wnuk 5, Novartis, Sandoz 0 Comment

After disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo

Novartis sells parts of Sandoz for $1bn

https://pharmaphorum.com/news/novartis-sells-sandoz-parts/

News/ Pfizer/ Rare diseases

Pfizer axes development of Duchenne muscular dystrophy antibody

Piotr Wnuk DMD, Duchenne, Duchenne muscular dystrophy, Pfizer, rare disease 0 Comment

Pfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy

Pfizer axes development of Duchenne muscular dystrophy antibody

https://pharmaphorum.com/news/duchenne-trials-axed-pfizer-dmd/

AstraZeneca/ Diabetes/ Diabetes/ News/ News/ R&D/ UK & Europe

AstraZeneca improves diabetes pen to maintain its market share

Piotr Wnuk AstraZeneca, Bydureon, Diabetes, GLP-1 0 Comment

The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug

AstraZeneca improves diabetes pen to maintain its market share

https://pharmaphorum.com/news/astrazeneca-improves-diabetes-pen-to-maintain-its-market-share/

AbbVie/ Market Access/ News/ News/ Top stories

AbbVie braces for impact of Humira biosimilars in Europe

Piotr Wnuk AbbVie, biosimilar, biosimilars Europe, Humira 0 Comment

AbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European

AbbVie braces for impact of Humira biosimilars in Europe

https://pharmaphorum.com/news/abbvie-braces-for-impact-of-humira-biosimilars-in-europe/

News/ News/ Pfizer/ R&D

Pfizer drug reduces mortality in patients with fatal heart disease

Joy Persaud cardiology, Pfizer, tafamidis 0 Comment

Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase

Pfizer drug reduces mortality in patients with fatal heart disease

https://pharmaphorum.com/news/tafamidis-reduces-mortality/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Top pharmaceutical companies

Login